1. Home
  2. Journal
  3. Retatrutide side effects in trials
Trial data

Retatrutide Side Effects Reported in Clinical Trials

Gastrointestinal effects were the most commonly reported adverse events in retatrutide trials. This guide summarises what the phase 2 and phase 3 reports said and how to read the numbers.

Trial dataPublished Updated 4 min read754 words

Research disclaimer For educational purposes only. Products are supplied strictly for laboratory research use. Not medical advice. Not for human or animal consumption.

Summary

Across the published retatrutide trials, gastrointestinal events were the most commonly reported adverse events. They included nausea, diarrhoea, vomiting and constipation, and they were dose related and most frequent during dose escalation. Skin sensitivity (dysaesthesia) was reported more often than with placebo, and heart rate rose in a dose related way before declining. Discontinuation because of adverse events varied by dose and trial.

This is a summary of trial reports on an investigational medicine, not medical advice.

Phase 2 findings

In the 48 week phase 2 trial in the [[New England Journal of Medicine|https://www.nejm.org/doi/full/10.1056/NEJMoa2301972]], 82% of retatrutide participants reported any adverse event against 70% with placebo. Overall incidence of nausea was 27%, diarrhoea 13%, vomiting 10% and constipation 9%. Serious adverse events were 4% in both the retatrutide and placebo groups. Discontinuation because of adverse events was 8% overall, ranging from 6% to 16% across retatrutide groups, against 0% with placebo.

Gastrointestinal effects

These effects are typical of peptides that act on GLP-1, a hormone that slows gastric emptying. They were more frequent at higher doses and are the main reason trials increase dose gradually. In phase 2, a lower starting dose partly reduced them. See [[dose response in the trials|/blog/retatrutide-dose-response-trials]].

Phase 3 findings

Eli Lilly reported 80 week phase 3 results in July 2026. In TRIUMPH-2 (type 2 diabetes with obesity or overweight), diarrhoea was reported by 27.4% at 4 mg, 33.5% at 9 mg and 33.6% at 12 mg, against 13.2% with placebo. Nausea was 13.7%, 20.8% and 28.0%, against 8.0%. In TRIUMPH-3 (severe obesity with cardiovascular disease), diarrhoea was 30.1% at 9 mg and 24.4% at 12 mg, against 8.7%, and nausea was 21.7% and 22.4%, against 5.8%.

Discontinuation because of adverse events in TRIUMPH-2 was 3.8% at 4 mg, 11.6% at 9 mg and 7.7% at 12 mg, against 4.9% with placebo. In TRIUMPH-3 it was 9.8% at 9 mg and 13.5% at 12 mg, against 4.8%. These figures come from a sponsor news release, so check the full papers when published.

Skin sensitivity

Dysaesthesia, an abnormal skin sensation such as tingling or heightened sensitivity, was reported more often with retatrutide than placebo. In phase 2 it was about 7% against 1%, and none of the events were severe, serious or led to stopping. In phase 3 it ranged from 4.5% to 7.3% across retatrutide groups against 0.7% to 1.3% with placebo.

Heart rate and other findings

The phase 2 paper reported a dose related increase in heart rate that peaked at 24 weeks and then declined, which the authors described as similar to that seen with GLP-1 receptor agonists. It reported no clinically significant hypoglycaemia, and one serious adverse event of acute pancreatitis. Read the paper for the full adverse event tables.

Glucose, liver and other safety observations

The phase 2 paper reported that ALT, a liver enzyme, rose above three times the upper limit of normal in 1% of retatrutide participants. It reported no medullary thyroid cancer or C cell hyperplasia. In TRIUMPH-3, hyperglycaemia was reported less often with retatrutide (3.9% at 9 mg and 3.1% at 12 mg) than with placebo (13.4%), which fits the improved glucose control seen with these peptides.

Why placebo groups report events too

People taking placebo also report nausea, diarrhoea and other symptoms, so the raw rate for retatrutide overstates what is attributable to it. In TRIUMPH-2, placebo diarrhoea was 13.2% and nausea 8.0%. In TRIUMPH-3 they were 8.7% and 5.8%. The gap between retatrutide and placebo is the better guide, and it widened with dose.

Context from similar peptides

Semaglutide and tirzepatide show a similar pattern of mostly gastrointestinal events. See [[how the three compare|/blog/retatrutide-vs-tirzepatide-semaglutide]]. Differences in design, dose and population make direct comparison between trials unreliable.

What trial safety data does not cover

Trial safety data comes from selected participants under medical supervision using the investigational medicine. It does not describe laboratory research materials, unsupervised use or long term effects beyond the study periods. Retatrutide has no UK marketing authorisation. See [[is retatrutide legal in the UK|/blog/is-retatrutide-legal-uk]].

References and evidence context

Jastreboff et al., Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial, New England Journal of Medicine, 2023

Eli Lilly, retatrutide phase 3 TRIUMPH-2 and TRIUMPH-3 results, news release, 23 July 2026

Figures are as reported in the sources named at the time of writing. Phase 3 figures come from the sponsor news release, so check the peer reviewed papers for full methods and safety tables when published. This is general information about published research, not medical advice.

Frequently asked questions

What are the most common retatrutide side effects in trials?

Gastrointestinal events such as nausea, diarrhoea, vomiting and constipation were most commonly reported.

Are retatrutide side effects dose related?

In the trials, gastrointestinal events were more frequent at higher doses and during dose escalation.

How many people stopped because of side effects?

In phase 2, 8% overall. In the phase 3 trials, between 3.8% and 13.5% depending on dose and trial, against 4.8% to 4.9% with placebo.

What is retatrutide dysaesthesia?

Abnormal skin sensation, such as tingling or sensitivity, reported in about 5% to 7% of retatrutide participants in trials, against 1% or less with placebo.

Is this medical advice?

No. Speak to a clinician about medical questions. Retatrutide is investigational and not licensed in the UK.

Important information

Research use only. Not a medicine, not a supplement, not approved for human or animal use.

Cambridge Health™ does not provide usage, dosage, reconstitution or administration guidance for any product. Product information on this page is provided for research and educational context only.

  • Supplied strictly for laboratory and analytical research use. Not for human or animal consumption.
  • No medical advice, treatment guidance or personal use recommendations are provided.
  • Buyers are solely responsible for ensuring that the purchase, import, handling and use of research materials is lawful in their jurisdiction.

Supplied for laboratory research use only. Not a licensed medicine and not approved for human or animal use.

Related

Enquire about research supply

Cambridge Health supplies retatrutide research vials and the RetaPen research pen for laboratory research only.

Submit a purchase request Chat on Telegram

Enquire about research supply

Cambridge Health supplies research peptides to UK laboratories. Submit a research enquiry to discuss availability.

Chat on Telegram